Business Description
ISIN : US2183521028
Share Class Description:
CORT: Ordinary SharesTotal Employee Number:
730Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 32.71 | |||||
Equity-to-Asset | 0.79 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | 1.07 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 44.93 | |||||
Beneish M-Score | -2.58 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 22.3 | |||||
3-Year EBITDA Growth Rate | -27 | |||||
3-Year EPS without NRI Growth Rate | -2 | |||||
3-Year FCF Growth Rate | 4.6 | |||||
3-Year Book Growth Rate | 9.5 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 109.34 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 42.7 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 52.26 | |||||
9-Day RSI | 61.88 | |||||
14-Day RSI | 64.29 | |||||
3-1 Month Momentum % | 57.99 | |||||
6-1 Month Momentum % | 166.52 | |||||
12-1 Month Momentum % | 37.07 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.86 | |||||
Quick Ratio | 2.77 | |||||
Cash Ratio | 2 | |||||
Days Inventory | 329.46 | |||||
Days Sales Outstanding | 27.24 | |||||
Days Payable | 759.96 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 0.6 | |||||
Shareholder Yield % | -0.01 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 98.31 | |||||
Operating Margin % | 0.77 | |||||
Net Margin % | 6.64 | |||||
EBITDA Margin % | 1.06 | |||||
FCF Margin % | 12.87 | |||||
OCF Margin % | 13.2 | |||||
ROE % | 8.47 | |||||
ROA % | 6.62 | |||||
ROIC % | 1.41 | |||||
3-Year ROIIC % | -16.75 | |||||
ROC (Joel Greenblatt) % | 74.45 | |||||
ROCE % | 0.95 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 285.24 | |||||
Forward PE Ratio | 69.41 | |||||
PE Ratio without NRI | 285.24 | |||||
Shiller PE Ratio | 123.23 | |||||
Price-to-Owner-Earnings | 861.87 | |||||
PS Ratio | 16.72 | |||||
PB Ratio | 18.32 | |||||
Price-to-Tangible-Book | 18.32 | |||||
Price-to-Free-Cash-Flow | 136.91 | |||||
Price-to-Operating-Cash-Flow | 133.41 | |||||
EV-to-EBIT | 1975.24 | |||||
EV-to-EBITDA | 1433.59 | |||||
EV-to-Revenue | 15.23 | |||||
EV-to-Forward-Revenue | 11.3 | |||||
EV-to-FCF | 118.32 | |||||
Price-to-GF-Value | 1.7 | |||||
Price-to-Projected-FCF | 5.31 | |||||
Price-to-Median-PS-Value | 2.1 | |||||
Price-to-Graham-Number | 15.24 | |||||
| Price-to-Net-Current-Asset-Value | 50.34 | |||||
| Price-to-Net-Cash | 103.28 | |||||
Earnings Yield (Greenblatt) % | 0.05 | |||||
FCF Yield % | 0.83 | |||||
Forward Rate of Return (Yacktman) % | -4.84 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CORT
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Corcept Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 830.813 | ||
| EPS (TTM) ($) | 0.42 | ||
| Beta | 0.1007 | ||
| 3-Year Sharpe Ratio | 0.96 | ||
| 3-Year Sortino Ratio | 1.77 | ||
| Volatility % | 91.48 | ||
| 14-Day RSI | 64.29 | ||
| 14-Day ATR ($) | 4.44664 | ||
| 20-Day SMA ($) | 115.6135 | ||
| 12-1 Month Momentum % | 37.07 | ||
| 52-Week Range ($) | 28.6601 - 126.3833 | ||
| Shares Outstanding (Mil) | 108.1 |
Piotroski F-Score Details
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Corcept Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Corcept Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-24 17:00 | In 182 days | ||
| Annual report for 2026 | 2027-02-24 | In 181 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-24 | In 181 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-04 17:00 | In 70 days | ||
| Third quarter earnings results for 2026 | 2026-11-04 | In 69 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-29 17:00 | 94.19 (+3.63%) | ||
| Second quarter earnings results for 2026 | 2026-07-29 | 94.19 (+3.63%) | ||
| General meeting for 2026 | 2026-05-21 07:30 | 59.06 (+0.72%) | ||
| First quarter earnings conference call for 2026 | 2026-04-30 17:00 | 46.59 (+0.82%) | ||
| First quarter earnings results for 2026 | 2026-04-30 | 46.59 (+0.82%) |
Corcept Therapeutics Inc Frequently Asked Questions
Guru Commentaries on NAS:CORT
Corcept Therapeutics (CORT) reported a successful Phase III result for an ovarian cancer treatment and was rewarded handsomely. This positive outcome highlights the company's potential for growth and value creation in the health care sector, particularly in oncology, which is a critical area of focus. The successful trial results not only enhance Corcept's market position but also contribute to the overall performance of the Small Cap Quality Growth portfolio, indicating strong confidence in its future prospects.
Corcept Therapeutics Inc. (CORT) had a negative impact on performance due to the fund not owning the stock. The stock rose sharply at quarter end after management reported positive results from the phase three study of ROSELLA, an ovarian cancer treatment. However, the fund's lack of exposure to this stock indicates a cautious stance on its future performance, especially given the mixed sector performance and broader market uncertainties.
Corcept Therapeutics Inc. (CORT) had a negative impact on performance as the fund did not own the stock. The stock rose sharply at quarter end after management reported positive results from the phase three study of ROSELLA, an ovarian cancer treatment. However, the fund's lack of exposure to this stock was noted as a detractor, indicating a missed opportunity in a potentially strong investment.
Corcept Therapeutics Inc. (CORT) had a negative impact on performance as the fund did not own the stock. The stock rose sharply at quarter end after management reported positive results from the phase three study of ROSELLA, an ovarian cancer treatment. However, the fund's lack of exposure to this stock was detrimental, indicating a missed opportunity in a potentially strong investment.
Press Release
Articles on Corcept Therapeutics Inc
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
